Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2009 - 2026)

Regeneron Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 4.13% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 4.13% decrease from a year earlier, with the FY2025 full-year figure at $3.1 billion, up 25.32% from the prior year.
• Cash & Equivalents declined to $3.0 billion in Q1 2026 per REGN's latest filing, from $3.1 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $3.9 billion in Q1 2023 and bottomed at $1.9 billion in Q2 2024.
• The 5-year median for Cash & Equivalents is $2.7 billion (2023), against an average of $2.8 billion.
• Across the five-year window, Cash & Equivalents surged 132.68% in 2022 and tumbled 42.94% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $3.1 billion in 2022, then slipped by 12.1% to $2.7 billion in 2023, then retreated by 8.86% to $2.5 billion in 2024, then advanced by 25.32% to $3.1 billion in 2025, then dropped by 4.99% to $3.0 billion in 2026.
• Per Business Quant, the three latest REGN Cash & Equivalents figures stand at $3.0 billion (Q1 2026), $3.1 billion (Q4 2025), and $2.5 billion (Q3 2025).